Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
   Guideline
2. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study.Frontiers in endocrinology · 2020
   Trial
3. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024
   Review
4. Mitochondrial Alpha-Keto Acid Dehydrogenase Complexes: Recent Developments on Structure and Function in Health and Disease.Sub-cellular biochemistry · 2024
   Review
5. Defective function of α-ketoglutarate dehydrogenase exacerbates mitochondrial ATP deficits during complex I deficiency.Redox biology · 2023
   Article
6. Update on the genetics of paragangliomas.Endocrine-related cancer · 2023
   Review
7. Pheochromocytoma: a changing perspective and current concepts.Therapeutic advances in endocrinology and metabolism · 2023
   Review
8. New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.Cancers · 2022
   Review
9. An original cuproptosis-related genes signature effectively influences the prognosis and immune status of head and neck squamous cell carcinoma.Frontiers in genetics · 2022
   Article
10. Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.Frontiers in endocrinology · 2022
    Article
11. Ovarian cancer modulates the immunosuppressive function of CD11bMolecular metabolism · 2021
    Article
12. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.Endocrine-related cancer · 2020
    Review
13. MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.PLoS genetics · 2020
    Article
14. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options.Gland surgery · 2020
    Review
15. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.Frontiers in endocrinology · 2020
    Review
16. Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin.Cancers · 2019
    Review

Corrections and comments

• Erratum for
  Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.2019

Authors and funding

28 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.